Genmab A/S
Records under this name other than the patents Genmab A/S holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 87 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,457,735 | Methods of Inducing T Cell Activation by Administering an Antibody Comprising CD40 and 4-1BB (CD137) Binding Domains now held by BioNTech SE In force · High confidence | In force | High confidence | |
| US 10,927,181 | Agonistic Tumor Necrosis Factor (TNF) Receptor Binding Agents now held by BioNTech SE In force · High confidence | In force | High confidence | |
| US 11,814,411 | Nucleic Acid Molecules Encoding Binding Agents to CD40 and 4-1BB (CD137) now held by BioNTech SE In force · High confidence | In force | High confidence | |
| US 10,364,285 | Agents, Uses and Methods for the Treatment of Synucleinopathy conveyed to H. Lundbeck A/S In force · High confidence | In force | High confidence | |
| US 10,428,147 | Anti-Sortilin Antibodies, Uses and Methods for Treatment conveyed to H. Lundbeck A/S In force · High confidence | In force | High confidence | |
| US 10,479,835 | Agent, Uses and Methods for Treatment conveyed to H. Lundbeck A/S In force · High confidence | In force | High confidence | |
| US 10,640,554 | Agents, Uses and Methods for the Treatment of Synucleinopathy conveyed to H. Lundbeck A/S In force · High confidence | In force | High confidence | |
| US 10,647,763 | Agents, Uses and Methods for the Treatment of Synucleinopathy conveyed to H. Lundbeck A/S In force · High confidence | In force | High confidence | |
| US 10,647,764 | Agents, Uses and Methods for the Treatment of Synucleinopathy conveyed to H. Lundbeck A/S In force · High confidence | In force | High confidence | |
| US 10,800,836 | Agents, Uses and Methods for the Treatment of Synucleinopathy conveyed to H. Lundbeck A/S In force · High confidence | In force | High confidence |